Timing of Chemotherapy Initiation May Affect Advanced Ovarian Cancer Survival

Survival for women with advanced ovarian cancer may be negatively impacted when chemotherapy is initiated more than 25 days after surgery.
Survival for women with advanced ovarian cancer may be negatively impacted when chemotherapy is initiated more than 25 days after surgery.

Survival for women with advanced ovarian cancer may be negatively impacted when chemotherapy is initiated more than 25 days after surgery, a new study published online ahead of print in the journal Annals of Oncology has shown.1

For the study, researchers sought to evaluate whether time elapsed between surgery and initiation of chemotherapy affects survival in patients with advanced ovarian carcinoma.

Researchers conducted a posttrial ad hoc analysis of Gynecologic Oncology Group protocol 218, a randomized, double-blind, placebo-controlled phase 3 trial that assessed bevacizumab as primary and maintenance therapy for patients with newly diagnosed ovarian cancer.

In this analysis, researchers analyzed data from 1718 evaluable patients with stage 3 or 4 ovarian carcinoma. Of those, 701 patients had low volume residual, 932 had suboptimal volume residual, and 81 patients with stage 4 disease had undergone complete resection.

Results showed that time to chemotherapy initiation was associated with improved overall survival. Researchers found those who underwent complete resection had an increased risk of mortality when initiation of chemotherapy exceeded 25 days after surgery.

The American Cancer Society estimates that approximately 21 291 women with be diagnosed with ovarian cancer in the United States in 2015 and approximately 14 180 women will die from the disease.

REFERENCE

1. Tewari KS, Java JJ, Monk BJ, Burger RA. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: an NRG Oncology/Gynecologic Oncology Group Study [published online ahead of print on October 20, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv500.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs